February 12, 2025 01:23 PM EST

Pfizer wins approval in new indication for blood cancer drug Adcetris

Alexis Kramer

Pharma Editor

Pfizer secured an eighth indication for its blood cancer drug Adcetris after the FDA approved its use in adults, in combination with two other medications …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer wins approval in new indication for blood cancer drug Adcetris

Alexis Kramer

Pharma Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

AbbVie pens another T cell engager deal, this time with Xilio

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Major FDA staff cuts would slow drug reviews, experts say

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Pfiz­er wins ap­proval in new in­di­ca­tion for blood can­cer drug Ad­cetris

Pharma Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer wins approval in new indication for blood cancer drug Adcetris